See Graham's ranking
4.0
Halozyme Therapeutics Inc. is a healthcare company operating in the biotechnology industry. Founded in 1998 in the United States, the company specializes in developing technologies that make drug administration more efficient and accessible for patients and healthcare professionals.
The company’s core innovation is the Enhanze platform, which is based on a recombinant human hyaluronidase enzyme. This technology enhances the absorption of drugs into subcutaneous tissue, allowing biologic therapies previously administered intravenously to be delivered more quickly and conveniently. Companies such as Roche, Pfizer, Bristol-Myers Squibb, and AbbVie use this platform to optimize their own treatments.
With a global footprint, Halozyme operates through partnerships with major pharmaceutical and biotechnology companies. Its revenue is primarily derived from licensing the Enhanze technology, royalties on products that incorporate its innovation, and milestone payments tied to the development and approval of new formulations.
The market for injectable therapies is rapidly evolving, driven by the demand for greater patient convenience and product differentiation in the biopharmaceutical sector. Halozyme competes with other drug-delivery platforms while also navigating regulatory challenges that directly influence product launches and corporate growth.
Halozyme maintains a lean organizational structure, with roughly 132 employees and corporate headquarters in San Diego, California. Its focus centers on research and development of new technologies, along with contract management and intellectual property stewardship, continually seeking innovations that benefit both patients and commercial partners.
The company’s shares trade on the Nasdaq under the ticker HALO.
History and foundation
Halozyme Therapeutics Inc. was founded in 1998 in San Diego, California, with the goal of developing innovative drug-delivery technologies, particularly for the biopharmaceutical industry.
In its early years, the company faced challenges related to developing and validating the Enhanze platform, as well as securing strategic partnerships. As research progressed, Halozyme secured initial agreements that helped establish its market presence.
The company went public in 2004 through an initial public offering (IPO) on the Nasdaq, raising capital to advance its research efforts and expand strategic collaborations. Throughout the 2010s, Halozyme strengthened its licensing- and royalty-based business model, forming partnerships with major pharmaceutical companies such as Roche and Pfizer.
Expansion efforts included broadening applications of the Enhanze platform across a wider range of therapeutics, as well as investing in new applications for oncology and in improved subcutaneous delivery of biologic therapies.
Between 2020 and 2024, Halozyme expanded its partnership portfolio, achieving record revenue and profitability. The company also executed strategic acquisitions to reinforce its position in the sector, enhanced its research initiatives, and accelerated the development of new drug-delivery technologies to keep pace with the evolution of the biopharmaceutical industry and patient needs.
Additional Information
The Company Halozyme Therapeutics Inc. (United States), is listed on Nasdaq with a market cap of $ 8.23 Billions, having an equity of $ 503.92 Millions.
With a total of 132 employees, the company is listed in the sector of Health Care and categorized in industry of Biotechnology.
In the last 12 months the Company had a revenue of $ 1.24 Billion, which generated a profit in the amount of $ 595.48 Millions.
As for its main indicators, the Company has a P/E ratio of 13.82, a P/BV ratio of 16.33 and in the last 12 months the Company did not pay dividends.
The Company is traded internationally through the ticker HALO.
